News

Patient Views – August/September Methodology

BY DSN STAFF

AccentHealth collected data through an online survey conducted from July 19 to Aug. 1, 2012. There were a total of 745 respondents who were recruited via AccentHealth’s national, online panel of network viewers ages 18 years and up who opt-in to participate in reasearch with AccentHealth. Below is the demographic breakdown of those respondents and their behavior:

Number of annual pharmacy visits

 

Number of annual prescription fills


 

Age

Employment status

Income

 

Gender

Health insurance coverage

 

Geographic distribution of sample

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

SoloHealth, Dell partner on health kiosks

BY Alaric DeArment

ATLANTA — Health kiosk manufacturer SoloHealth is in a deal with computer maker Dell to produce kiosks that it will deliver to retail locations around the country starting in the fall, the companies said Monday.

Under the partnership, Dell will use its OEM Solutions technology to develop the latest version of the SoloHealth Station consumer kiosk, an interactive and comprehensive health-and-wellness screening kiosk for consumers placed in high-traffic retail locations and areas, such as corporate campuses and hospitals that provides screenings for vision, blood pressure, weight and body mass index, as well as a symptom checker and an overall health assessment. The kiosks also can connect users with local medical professionals through a database.

"Dell is a perennial brand and leader in technology solutions and innovation, and this partnership will allow us to produce and deliver the most innovative and comprehensive consumer health and wellness kiosk available to thousands of retail locations nationwide," SoloHealth CEO Bart Foster said. "We strive daily to deliver a superior product and service, and this partnership with Dell allows us to continue on that promise."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

FDA approves generic version of Actos

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic version of a diabetes drug made by Takeda, the agency said Friday.

The FDA announced the approval of Mylan’s pioglitazone hydrochloride tablets in the 15-mg, 30-mg and 45-mg strengths. The drug is a generic version of Takeda’s Actos. Mylan announced its launch of the drug at the same time as the FDA’s announcement, also announcing the launch of its previously approved generic version of Actoplus Met (pioglitazone hydrochloride and metformin) tablets in the 15-mg/500-mg and 15-mg/850-mg strengths.

Actos had sales of $2.7 billion during the 12-month period ended in June, according to IMS Health. Versions of Actoplus Met had sales of about $413 million during the same period.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES